Tag: Presents

Latest News

Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

Newsemia
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of...
Latest News

Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human primates that demonstrate the successful use...
Latest News

Tandem Diabetes Care Presents Positive Real-world Data from Automated Insulin Delivery Systems at American Diabetes Association Scientific Sessions

Newsemia
SAN DIEGO–(BUSINESS WIRE)—- $TNDM #ADA2020–Tandem presents positive real-world data from early use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology....
Latest News

LEO Pharma Presents Results From Study of Twice-Weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for Topical Use in Long-Term Maintenance Treatment of Plaque Psoriasis

Newsemia
BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma presents results from study of twice-weekly Enstilar® (calcipotriene and betamethasone dipropionate) Foam for topical use in long-term main Source link...
Latest News

Alnylam Presents Positive Phase 3 Results from ILLUMINATE-A Study of Lumasiran, an Investigational RNAi Therapeutic for Treatment of Primary Hyperoxaluria Type 1

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an...
Latest News

Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® (patisiran) at the European Academy of Neurology Virtual Congress 2020

Newsemia
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from the Global Open-Label Extension (OLE) study of ONPATTRO®...
Gastroenterology

The American Journal of Gastroenterology Presents "The Negative Issue"

Newsemia
Clinical studies with negative findings are the focus of a new “Negative Issue” of The American Journal of Gastroenterology (AJG) dedicated to studies with negative...
Latest News

Global Influenza Diagnostics Industry (2020 to 2025) – Advancements in Genomic and Proteomic Technologies Presents Opportunities – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user...
Latest News

Insights on the European Immunochemistry Industry to 2027 – Rising Healthcare Expenditure in Europe Presents Lucrative Opportunities – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Europe Immunochemistry Market to 2027 – Regional Analysis and Forecasts by Application; Product; End User, and Country” report has been added to ResearchAndMarkets.com’s...
Latest News

Detailed Insights into the Global Spine Implant Market (2020 to 2024) – A Rising Geriatric Population Presents Opportunities – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Global Spine Implant Market: Size, Trends & Forecasts (2020-2024)” report has been added to ResearchAndMarkets.com’s offering. This report provides an analysis of the...
Latest News

Onduo Presents Data on High Satisfaction and Positive Glycemic Outcomes With the Use of Continuous Glucose Monitoring Through Its Virtual Diabetes Clinic

Newsemia
BOSTON–(BUSINESS WIRE)– #ATTD2020–Today, Onduo shared positive research findings from the use of continuous glucose monitoring (CGM) systems by adults with type 2 diabetes participating in...
Latest News

Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort Showing Potential of Topical Ocular Formulation of AKB-9778 Product Candidate When Combined with Prostaglandin in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension

Newsemia
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, announced that...
Latest News

Latin America 3D Cell Culture Market 2019-2027 – Increasing Usage of 3D Cell Culture in Organ Transplantation & Drug Screening Presents Lucrative Opportunities – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The “Latin America 3D Cell Culture Market 2019-2027” report has been added to ResearchAndMarkets.com’s offering. The Latin America market for 3D cell culture has...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World